108 related articles for article (PubMed ID: 21824093)
1. The "STEP-wise" future of adenovirus-based HIV vaccines.
Patterson LJ
Curr Med Chem; 2011; 18(26):3981-6. PubMed ID: 21824093
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
Duerr A; Huang Y; Buchbinder S; Coombs RW; Sanchez J; del Rio C; Casapia M; Santiago S; Gilbert P; Corey L; Robertson MN;
J Infect Dis; 2012 Jul; 206(2):258-66. PubMed ID: 22561365
[TBL] [Abstract][Full Text] [Related]
3. Use of adenovirus in vaccines for HIV.
Patterson S; Papagatsias T; Benlahrech A
Handb Exp Pharmacol; 2009; (188):275-93. PubMed ID: 19031031
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
5. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
6. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
[TBL] [Abstract][Full Text] [Related]
7. Nonreplicating vectors in HIV vaccines.
Johnson JA; Barouch DH; Baden LR
Curr Opin HIV AIDS; 2013 Sep; 8(5):412-20. PubMed ID: 23925001
[TBL] [Abstract][Full Text] [Related]
8. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
9. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus vectors as HIV-1 vaccines: where are we? What next?
DʼSouza MP; Yang OO
AIDS; 2015 Feb; 29(4):395-400. PubMed ID: 25630039
[No Abstract] [Full Text] [Related]
11. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.
Frahm N; DeCamp AC; Friedrich DP; Carter DK; Defawe OD; Kublin JG; Casimiro DR; Duerr A; Robertson MN; Buchbinder SP; Huang Y; Spies GA; De Rosa SC; McElrath MJ
J Clin Invest; 2012 Jan; 122(1):359-67. PubMed ID: 22201684
[TBL] [Abstract][Full Text] [Related]
12. Rare serotype adenoviral vectors for HIV vaccine development.
Michael NL
J Clin Invest; 2012 Jan; 122(1):25-7. PubMed ID: 22201675
[TBL] [Abstract][Full Text] [Related]
13. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR
Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.
Hayes PJ; Cox JH; Coleman AR; Fernandez N; Bergin PJ; Kopycinski JT; Nitayaphan S; Pitisuttihum P; de Souza M; Duerr A; Morgan C; Gilmour JW
AIDS; 2016 Jul; 30(11):1703-12. PubMed ID: 27088318
[TBL] [Abstract][Full Text] [Related]
15. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
Sekaly RP
J Exp Med; 2008 Jan; 205(1):7-12. PubMed ID: 18195078
[TBL] [Abstract][Full Text] [Related]
16. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
Auclair S; Liu F; Niu Q; Hou W; Churchyard G; Morgan C; Frahm N; Nitayaphan S; Pitisuthithum P; Rerks-Ngarm S; Kimata JT; Soong L; Franchini G; Robb M; Kim J; Michael N; Hu H
PLoS Pathog; 2018 Feb; 14(2):e1006888. PubMed ID: 29474461
[TBL] [Abstract][Full Text] [Related]
17. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Haut LH; Ertl HC
J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
[TBL] [Abstract][Full Text] [Related]
19. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
[TBL] [Abstract][Full Text] [Related]
20. HIV/AIDS vaccines: a need for new concepts?
Girard MP; Bansal GP
Int Rev Immunol; 2008; 27(6):447-71. PubMed ID: 19065351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
